Your browser is no longer supported. Please, upgrade your browser.
Arbutus Biopharma Corporation
Index- P/E- EPS (ttm)-0.96 Insider Own1.40% Shs Outstand93.43M Perf Week-19.02%
Market Cap269.70M Forward P/E- EPS next Y-0.68 Insider Trans-4.21% Shs Float63.50M Perf Month-14.59%
Income-78.60M PEG- EPS next Q-0.22 Inst Own25.30% Short Float6.65% Perf Quarter-32.29%
Sales7.50M P/S35.96 EPS this Y65.40% Inst Trans-0.30% Short Ratio2.08 Perf Half Y-8.17%
Book/sh-0.41 P/B- EPS next Y19.00% ROA-61.40% Target Price- Perf Year95.14%
Cash/sh1.37 P/C2.04 EPS next 5Y- ROE147.90% 52W Range1.24 - 9.02 Perf YTD-20.85%
Dividend- P/FCF- EPS past 5Y6.20% ROI122.00% 52W High-68.85% Beta2.93
Dividend %- Quick Ratio20.50 Sales past 5Y-21.60% Gross Margin- 52W Low126.61% ATR0.21
Employees78 Current Ratio20.50 Sales Q/Q40.00% Oper. Margin- RSI (14)33.48 Volatility6.77% 6.22%
OptionableYes Debt/Eq- EPS Q/Q15.70% Profit Margin- Rel Volume0.73 Prev Close2.80
ShortableYes LT Debt/Eq- EarningsMay 05 BMO Payout- Avg Volume2.03M Price2.81
Recom2.10 SMA20-12.78% SMA50-17.26% SMA200-20.45% Volume1,488,067 Change0.36%
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Oct-04-19Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18Upgrade B. Riley FBR Neutral → Buy $11.50 → $9
Oct-15-18Upgrade Wedbush Underperform → Neutral $5
Oct-12-18Reiterated Chardan Capital Markets Buy $12 → $6.50
Jul-06-18Downgrade B. Riley FBR, Inc. Buy → Neutral $9 → $9
Mar-19-18Resumed Chardan Capital Markets Buy $8.25
Mar-19-18Downgrade Wedbush Outperform → Neutral $9 → $6
Jan-05-18Initiated B. Riley FBR, Inc. Buy $10
Apr-04-17Upgrade Chardan Capital Markets Neutral → Buy $3 → $6
Feb-01-17Reiterated Wedbush Outperform $13 → $10
Dec-13-16Downgrade Chardan Capital Markets Buy → Neutral $4 → $3
May-06-21 12:31AM  
May-05-21 08:45AM  
May-03-21 07:00AM  
Apr-28-21 08:00AM  
Apr-16-21 01:21AM  
Mar-17-21 08:58AM  
Mar-16-21 07:30AM  
Mar-04-21 10:01PM  
Mar-03-21 10:42AM  
Mar-02-21 08:00AM  
Feb-26-21 11:52AM  
Feb-22-21 08:00AM  
Feb-14-21 11:14PM  
Jan-25-21 07:30AM  
Jan-04-21 08:00AM  
Dec-31-20 11:11PM  
Dec-15-20 08:52AM  
Dec-14-20 09:18AM  
Dec-12-20 04:02PM  
Dec-10-20 07:30AM  
Nov-16-20 07:00AM  
Nov-15-20 02:40PM  
Nov-12-20 08:32AM  
Nov-10-20 08:00AM  
Nov-07-20 07:06AM  
Nov-05-20 09:25AM  
Nov-04-20 09:21AM  
Oct-28-20 12:32PM  
Oct-16-20 06:01AM  
Oct-13-20 08:00AM  
Sep-28-20 08:00AM  
Sep-15-20 07:30AM  
Sep-09-20 08:00AM  
Aug-27-20 08:00AM  
Aug-26-20 08:40AM  
Aug-17-20 08:59AM  
Aug-12-20 11:27AM  
Aug-10-20 11:30AM  
Aug-07-20 08:55AM  
Aug-05-20 08:00AM  
Jul-31-20 12:30PM  
Jul-29-20 06:00PM  
Jul-27-20 12:31PM  
Jul-24-20 11:52PM  
Jul-23-20 05:39PM  
Jun-15-20 08:18PM  
May-27-20 08:00AM  
May-20-20 01:18PM  
May-19-20 11:11AM  
May-18-20 04:05PM  
May-15-20 11:04AM  
May-14-20 02:22PM  
May-12-20 08:00AM  
May-11-20 11:19AM  
May-04-20 08:00AM  
Apr-27-20 12:32PM  
Mar-31-20 08:47AM  
Mar-27-20 08:02AM  
Mar-26-20 04:05PM  
Mar-05-20 08:55AM  
Feb-27-20 12:30PM  
Feb-10-20 08:00AM  
Jan-02-20 05:05AM  
Dec-30-19 10:08AM  
Dec-27-19 09:04AM  
Dec-19-19 03:50PM  
Nov-06-19 09:35AM  
Nov-03-19 07:13AM  
Oct-30-19 10:33AM  
Oct-10-19 02:59PM  
Oct-04-19 07:32AM  
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.Chief Business OfficerFeb 09Sale5.0020,000100,0001,307,457Feb 10 05:06 PM
McElhaugh Michael J.Chief Business OfficerDec 14Sale5.0040,000200,0321,327,457Dec 16 04:33 PM
McElhaugh Michael J.Chief Business OfficerJul 23Sale5.0120,000100,2001,367,457Jul 27 05:27 PM